pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Pulmonary Arterial Hypertension Drug Information

Drug Information

Indication: Substitution treatment of essential HTN &/or stable CAD in patients already controlled w/ perindopril &...

Azoren
amlodipine besylate + olmesartan medoxomil

Indication: Essential HTN in patient whose BP is inadequately controlled on olmesartan medoxomil or amlodipine monotherapy...

Indication: 1st line treatment of HTN & myocardial ischemia whether due to fixed obstruction (stable angina) &/or ...

Indication: Pulmonary arterial HTN (PAH) in patients of WHO functional class II-IV.

Indication: Long-term treatment of pulmonary arterial HTN (PAH) in adult patients w/ WHO functional class II-III, includin...

Indication: HTN, vasospastic (Prinzmetal's or variant angina) or chronic stable angina.

Indication: 1st-line treatment of HTN & myocardial ischaemia. Monotherapy or in combination w/ other antianginal drugs...

Indication: HTN. 1st-line treatment of myocardial ischemia in fixed obstruction (stable angina) &/or vasoconstriction/...

Indication: 1st-line treatment for HTN as monotherapy or combination w/ other antihypertensive agents; myocardial ischemia...

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 18 Sep 2020
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, 4 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.